| Literature DB >> 23533419 |
W Buwembo1, S Aery, C M Rwenyonyi, G Swedberg, F Kironde.
Abstract
Cotrimoxazole inhibits dhfr and dhps and reportedly selects for drug resistance in pathogens. Here, Streptococcus mutans isolates were obtained from saliva of HIV/AIDS patients taking cotrimoxazole prophylaxis in Uganda. The isolates were tested for resistance to cotrimoxazole and their folP DNA (which encodes sulfonamide-targeted enzyme dhps) cloned in pUC19. A set of recombinant plasmids carrying different point mutations in cloned folP were separately transformed into folP-deficient Escherichia coli. Using sulfonamide-containing media, we assessed the growth of folP-deficient bacteria harbouring plasmids with differing folP point mutations. Interestingly, cloned folP with three mutations (A37V, N172D, R193Q) derived from Streptococcus mutans 8 conferred substantial resistance against sulfonamide to folP-deficient bacteria. Indeed, change of any of the three residues (A37V, N172D, and R193Q) in plasmid-encoded folP diminished the bacterial resistance to sulfonamide while removal of all three mutations abolished the resistance. In contrast, plasmids carrying four other mutations (A46V, E80K, Q122H, and S146G) in folP did not similarly confer any sulfonamide resistance to folP-knockout bacteria. Nevertheless, sulfonamide resistance (MIC = 50 μ M) of folP-knockout bacteria transformed with plasmid-encoded folP was much less than the resistance (MIC = 4 mM) expressed by chromosomally-encoded folP. Therefore, folP point mutations only partially explain bacterial resistance to sulfonamide.Entities:
Year: 2013 PMID: 23533419 PMCID: PMC3596926 DOI: 10.1155/2013/367021
Source DB: PubMed Journal: Int J Microbiol
Figure 1Flow chart showing characterization of folP gene. Plasmids carrying folP gene were transformed in folP gene knockout bacteria to determine the effect of different mutations in plasmid encoded folP on bacterial resistance to sulfonamides.
Characteristics of bacterial isolates used in the current study, the respective genes and susceptibility to Cotrimoxazole (STX), sulfamethoxazole (SMX), and trimethoprim (TMP) as determined by E-test.
| Isolate | Accession number of | Mutations in the | STX | Sulfonamide susceptibility | Trimethoprim susceptibility | Mutations in the |
|---|---|---|---|---|---|---|
|
| Not yet submitted to gene banks but previously published [ | A37V, N172D, and R193Q* | >32 | >1024 | >32 | None |
|
| HE599533.1 | A46V, E80K, Q122H, and S146G** | 0.5 | >1024 | 2 | None |
|
| Not yet submitted but previously published [ | A63S, W174LK, L175F, and M189I** | 8 | >1024 | 0.38 | None |
|
| HE 599535.1 | None | >32 | >1024 | >32 | None |
|
| Similar to ZP 07725257.1 | None | 0.125 | Not done | Not done | Not done |
*Mutations as compared to UA159 [10]. **Mutations as compared to NN2025 [11].
Primers used for cloning and site-directed mutagenesis.
| Primer name | Nucleotide sequence |
|
| |
| Mutans DHPSph | 5′-GAT CGA TCG CAT GCA CAT CAT AAC TAG GGA GCA AGC-3′ |
| mutansDHPSBam | 5′-GAT GGA TCG GAT CCA AAA TAATCT TAT CCA TAA CAC CCT CA-3′ |
| dhpssfwph | 5′-AAC CTA CTG CAT GCA TAA GAA TCA G-3′ |
| dhpssreveco | 5′-ATT GTA GGA ATT CTT CTA GAA AGA TCC-3′ |
| downeifolpfw | 5′-GCA TGC CAA AGA CAG GAA TTG CTG AC-3′ |
| Downeifolprevps | 5′-CTG CAG CCA CAA AAA TTT GCC CCA GAC-3′ |
|
| |
| Primers for changing specific amino acids in isolate 797 | |
|
| |
| DHPS46AVfw | 5′-TGA AGC CAT GTT AGT AGC AGG AGC GGC TA-3′ |
| DHPS46AVrev | 5′-TAG CCG CTC CTG CTA CTA ACA TGG CTT CA-3′ |
| DHPS80aEKfw | 5′-TCG TTC CAA TTG TTA AAG CTA TTA GCG AA-3′ |
| DHPS80aEKrev | 5′-TTC GCT AAT AGC TTT AAC AAT TGG AAC GA-3′ |
| DHPS122QHfw | 5′-CTT TAT GAT GGG CAC ATG TTT CAA TTA GC-3′ |
| DHPS122QHrev | 5′-GCT AAT TGA AAC ATG TGC CCA TCA TAA AG-3′ |
| DHPS146SGfw | 5′-GTG AAG AAG TTT ATG GCA ATG TAA CAG AA-3′ |
| DHPS146SGrev | 5′-TTC TGT TAC ATT GCC ATA AAC TTC TTC AC-3′ |
|
| |
| Primers for changing specific amino acids in isolate 8 | |
|
| |
| V37Afw | 5′-AAC CAA TCG ATC AGG CTC TAA AAC AGG TTG A-3′ |
| V37Arev | 5′-TCA ACC TGT TTT AGA GCC TGA TCG ATT GTT T-3′ |
| D172Nfw | 5′-GGA GTT AAA AAA GAA AAT ATT TGG CTT GAT C-3 |
| D172Nrev | 5′-GAT CAA GCC AAA TAT TTT CTT TTT TAA CTC C-3′ |
| Q193Rfw | 5′-ACA TGG AAC TTC TAC GAG GCT TAG CGG AGG T-3 |
| Q193Rrev | 5′-ACC TCC GCT AAG CCT CGT AGA AGT TCC ATG T-3′ |
Figure 2Comparing sulfamethoxazole minimal inhibitory concentrations (MICs) for folP knockout E. coli cells transformed with pUC19 plasmid carrying differing chromosomal folP genes of streptococci. To determine the effect plasmid encoded mutant folP has on the sulfamethoxazole resistance of transformed C600ΔfolP E. coli bacteria, growths (in SMX containing media) were compared for folP-deficient E. coli transformed with pUC19 carrying triple-mutant folP (residues 37, 172, and 193: bar A), double-mutant folP (bars B, C, and D), single-mutant folP (residue 193: bar E), and wild-type folP (bar F) from S. mutans isolate 8. The sulfamethoxazole resistance of transformed folP deficient cells was notably increased by transformation with plasmid encoding triple-mutated folP (wildtype folP MIC = 20 μM, triple-mutant folP MIC = 50 μM). Note: the MIC (sulfamethoxazole) for chromosome-encoded folP in S. mutans isolate 8 was 4 mM (see Table 1). Controls comprising C600ΔfolP E. coli transformed with pUC19 encoding either mutant folP from S. mutans isolates 797 (bar G) and 135 (bar H) or wild-type folP from S. sobrinus isolate 7 (bar I) or S. downei isolate 477 (bar J) showed basal or less sulfamethoxazole resistance (MICs = 20–30 μM). *: S. mutans isolate 8 mutant folP; **: S. mutans isolate 797 mutant folP; ***: S. mutans isolate 135 mutant folP.